Mycophenolate and SARS-CoV-2 vaccination: Mixing oil and water.

Abstract

The impact of coronavirus disease 2019 (COVID-19) in liver trans-plant (LT) patients during the first wave of the pandemic wasdevastating. Despite the use of face masks, social distancing andlockdowns adopted in some countries, the incidence of COVID- 19in LT patients was twice as high as that reported for age- matchednon-transplant population.1 This vulnerability motivated health-care authorities and regulators to grant an earlier access tovaccination programmes to patients receiving chronic immunosup -pression, including solid organ transplant recipients, even thoughthey had been systematically excluded from the registration trialsof vaccines against severe acute respiratory syndrome coronavi-rus 2 (SARS- CoV-2). When LT patients started to receive the vac-cine, the information regarding efficacy and safety in this specialpopulation was lacking. The accumulation of evidence in the lastmonths has provided some interesting data which should be takeninto account to maximize the effect of vaccination programmes inthis population